title: Potential of anti-Candida antibodies in immunoprophylaxis.
abstract: The need for new options for the treatment of invasive candidiasis has fuelled the use of antibodies in combination with conventional antifungal therapy. After a long period of time in which antibodies were considered irrelevant in the resistance against invasive candidiasis, it was demonstrated that a number of antibodies or their engineered derivatives directed against Candida albicans cell-wall polysaccharides and glycopeptides, as well as against some protein epitopes, confer protection against invasive candidiasis. This has confirmed this approach as a new strategy for the prophylaxis of invasive candidiasis. Of particular interest is Mycograb, a human recombinant monoclonal antibody that inhibits heat shock protein 90, and has been administrated in combination with lipid-associated amphotericin B to patients with invasive candidiasis, and the fungicidal anti-beta-glucan antibodies induced by the glycoconjugate vaccine composed of a beta-glucan polysaccharide conjugated with the diphtheria toxoid CRM 197. However, despite the promising data obtained in vitro and in animal models, at present there is very little clinical experience on the use of antibodies in Candida immunoprophylaxis.
authors.affiliation: Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Odontología, Universidad del País Vasco, Bilbao, Vizcaya, Spain.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Cabezas
authors.forename: Olatz
authors.initials: O
authors.lastname: Albaina
authors.forename: Dalila
authors.initials: D
authors.lastname: Montañez
authors.forename: María Jesús
authors.initials: MJ
authors.lastname: Sevilla
authors.forename: María D
authors.initials: MD
authors.lastname: Moragues
authors.forename: José
authors.initials: J
authors.lastname: Pontón
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000908:Antibodies, Fungal / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents / Q000627:therapeutic use; D000946:Antigens, Fungal / Q000276:immunology; D001426:Bacterial Proteins / Q000627:therapeutic use; D002176:Candida albicans / Q000276:immunology*; D002177:Candidiasis / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy; D000077336:Caspofungin; D002648:Child; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D054714:Echinocandins / Q000008:administration & dosage / Q000627:therapeutic use; D005657:Fungal Vaccines / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D055666:Lipopeptides; D051379:Mice; D009181:Mycoses / Q000517:prevention & control / Q000628:therapy; D016032:Randomized Controlled Trials as Topic
chemical_list: D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D000946:Antigens, Fungal; D001426:Bacterial Proteins; D054714:Echinocandins; D005657:Fungal Vaccines; D055666:Lipopeptides; C028581:CRM197 (non-toxic variant of diphtheria toxin); D000666:Amphotericin B; C512268:efungumab; D000077336:Caspofungin